Basic Information
| LncRNA/CircRNA Name | GAS6-AS2 |
| Synonyms | NA |
| Region | NA |
| Ensemble | ENSG00000272695 |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | cytarabine | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | acute myeloid leukemia |
| ICD-0-3 | NA |
| Methods | qPCR etc. |
| Sample | cell lines (MOLM14, K562, HEK293, HL60) |
| Expression Pattern | up-regulated |
| Function Description | Transcriptional activation of the GAS6-AS2 lncRNA, identified in our analysis, leads to hyperactivation of the GAS6/TAM pathway, a resistance mechanism in multiple cancers including AML. |
| Pubmed ID | 29677511 |
| Year | 2018 |
| Title | An Integrated Genome-wide CRISPRa Approach to Functionalize lncRNAs in Drug Resistance. |
External Links
| Links for GAS6-AS2 | GenBank HGNC NONCODE |
| Links for acute myeloid leukemia | OMIM COSMIC |